Another hurdle jumped for MBP8298
BioMS Medical completes patient recruitment in MINDSET-01 phase II relapsing-remitting multiple sclerosis trial
May 3 - CNW - BioMS Medical today announced that it has completed patient recruitment in its phase II clinical trial of MBP8298 for the treatment of relapsing-remitting MS (RRMS). The trial, named MINDSET-01, includes approximately 215 patients, and is being conducted at 24 trial sites in six countries across Europe.
"Reaching full recruitment in our relapsing-remitting MS trial in less than six months after initiating enrollment reflects the drive and dedication of our clinical team and all those involved in this trial," said Kevin Giese, President and CEO of BioMS Medical. "While there are current approved therapies for the relapsing-remitting form of MS, there is still a great need for treatments that are more convenient, safe and effective in treating the disease. MBP8298 has the potential to benefit patients with all forms of MS and with the long-term safety data it has generated to date, we believe MBP8298 would be greatly received."
The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS. The fifteen month trial will be followed by a 12 month active treatment open label extension period. The objectives of the study are to demonstrate safety and efficacy of MBP8298 versus placebo as measured by relapse rate, MRI activity and disease progression.
http://biz.yahoo.com/cnw/070503/bioms_m ... .html?.v=1